Autolus Therapeutics
Yahoo Finance • 9 days ago
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and... Full story
Yahoo Finance • 9 days ago
European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading
European equities traded in the US as American depositary receipts were tracking marginally lower la PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 11 days ago
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were trending lower late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 16 days ago
Autolus Therapeutics Q1 Earnings Call Highlights
Key Points Interested in Autolus Therapeutics PLC Sponsored ADR? Here are five stocks we like better. Autolus Therapeutics said first-quarter 2026 product revenue rose to $26.2 million, driven by early traction for AUCATZYL in the U.S. an... Full story
Yahoo Finance • 23 days ago
European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • last month
European Equities Traded in the US as American Depositary Receipts Decline Tuesday
European equities traded in the US as American depositary receipts were lower on Tuesday morning, do PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 2 months ago
Autolus Therapeutics to Participate in Upcoming Investor Conferences
LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies,... Full story
Yahoo Finance • 2 months ago
Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Mizuho lowered its price target on Autolus Therapeutics plc (NASDAQ:AUTL) to $10 from $12 previously and maintained an... Full story
Yahoo Finance • 2 months ago
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
European equities traded in the US as American depositary receipts were little changed late Friday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 2 months ago
Pre-Market Earnings Report for March 27, 2026 : CCL, TMC, CUK, KOPN, SBC, AUTL, SNWV, HUMA, SLE
The following companies are expected to report earnings prior to market open on 03/27/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Carnival Corporation (CCL)is reporting for the quarter ending Februa... Full story
Yahoo Finance • 2 months ago
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies,... Full story
Yahoo Finance • 3 months ago
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks
As February begins, the U.S. stock market is showing strength, with major indexes like the Dow Jones and S&P 500 posting significant gains. In this context of rising indices, investors often look for opportunities that may offer growth pot... Full story
Yahoo Finance • 5 months ago
Needham ups Autolus target, names top pick for 2026
Needham raised the firm’s price target on Autolus Therapeutics (AUTL) to $11 from $10 and keeps a Buy rating on the shares. The firm also names Autolus a top pick for 2026. While Aucatzyl’s launch has been impressive with $76M in sales, in... Full story
Yahoo Finance • 5 months ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 6 months ago
3 Promising Penny Stocks With Market Caps Over $70M
With the recent surge in U.S. stock markets following the Federal Reserve's interest rate cuts, investors are keenly observing how these changes might impact various sectors. While major indices like the S&P 500 and Dow Jones have shown si... Full story
Yahoo Finance • 6 months ago
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after infusion, suggesting... Full story
Yahoo Finance • 6 months ago
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity s... Full story
Yahoo Finance • 6 months ago
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that t... Full story
Yahoo Finance • 7 months ago
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story
Yahoo Finance • 7 months ago
Autolus outlines margin improvement and market share growth focus while expanding AUCATZYL to 60 U.S. centers
Earnings Call Insights: Autolus Therapeutics plc (AUTL) Q3 2025 MANAGEMENT VIEW * CEO Christian Itin reported the launch of AUCATZYL in the U.S. has reached market leadership in relapsed/refractory B-ALL, with broad access and reliable... Full story